Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2766471 | PMC |
| http://dx.doi.org/10.1111/j.1365-2125.2009.03490.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Bibliometric analysis of liposarcomas treatment from 2004 to 2023.
J Cancer Res Clin Oncol
January 2025
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Hepato-Pancreato-Biliary Surgery, Peking University Cancer Hospital & Institute, Beijing, 100142, P. R. China.
Background: Liposarcomas are mesenchymal malignant tumors characterized by varying degrees of adipocytic differentiation that comprises approximately 20% of soft tissue sarcomas. Despite advancements in this field, there remains a need for a comprehensive understanding of the mechanisms, diagnosis, and treatment of liposarcomas. Currently, there is a lack of bibliometric surveys on the development trajectory of liposarcomas treatment, research hotspots, and author and team collaboration.
View Article and Find Full Text PDFTrabectedin enhances the antitumor effects of IL-12 in triple-negative breast cancer.
Cancer Immunol Res
January 2025
The Ohio State University, Columbus, OH, United States.
Interleukin-12 (IL-12) is a potent NK cell-stimulating cytokine, but the presence of immunosuppressive myeloid cells such as myeloid-derived suppressor cells (MDSC) can inhibit IL 12-induced NK-cell cytotoxicity. Thus, we hypothesized that trabectedin, a myeloid cell-depleting agent, would improve the efficacy of IL-12 in triple-negative breast cancer (TNBC). In vitro treatment of healthy donor NK cells with trabectedin increased expression of the activation marker CD69 and mRNA expression of T BET (Tbx21), the cytotoxic ligands TRAIL (TNFSF10) and Fas ligand (FASLG) and the dendritic cell (DC)-recruiting chemokine lymphotactin (XCL1).
View Article and Find Full Text PDFConfirmatory diagnosis and successive chemotherapeutic treatments of metastatic skeletal sarcoma: A case report.
Oncol Lett
March 2025
Department of Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan.
sarcoma is rare and its clinical features remain unclear. Given the similarity in presentation, it is possible that previously reported cases of Ewing-like adamantinoma may have been sarcoma. The present case report describes a tumor in a 55-year-old man that was originally thought to be a Ewing-like adamantinoma, but was recently found to be an sarcoma following direct sequencing.
View Article and Find Full Text PDFSarcoma: Last Year's Practice Changing Papers.
Ann Surg Oncol
December 2024
Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Background: In 2023 and 2024, a wide variety of new studies have been published in the field of soft tissue sarcomas, representing the enormous heterogeneity of sarcoma histotypes, anatomical location, treatment variability, and biological behavior.
Patients And Methods: This article summarizes the, in our view, seven most important publications in the field that will have an impact on the surgical practice and future treatment strategies of our patients.
Results: In the last year, we gained more insight in the genetic background of patients with sarcoma from a large Australian study, which will have an impact on future counseling and screening of our patients.
[Through the labyrinth towards the goal: doxorubicin/trabectedin in metastatic and initially unresectable leiomyosarcoma].
Strahlenther Onkol
January 2025
Strahlenklinik, Universitätsklinikum Erlangen, Universitätsstr. 27, 91054, Erlangen, Deutschland.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!